Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption

The in vivo activity of a monoclonal antibody that targets the CD4 binding site on T cells and blocks HIV-1 binding was assessed. In this study of antiretroviral treatment interruption involving persons with HIV-1 infection, activity of UB-421 was shown.

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 380; no. 16; pp. 1535 - 1545
Main Authors Wang, Chang-Yi, Wong, Wing-Wai, Tsai, Hung-Chin, Chen, Yen-Hsu, Kuo, Be-Sheng, Lynn, Shugene, Blazkova, Jana, Clarridge, Katherine E, Su, Hsiao-Wen, Lin, Chia-Ying, Tseng, Fan-Chen, Lai, Annie, Yang, Fu-Hung, Lin, Chen-Han, Tseng, William, Lin, Hsiao-Yi, Finstad, Connie L, Wong-Staal, Flossie, Hanson, Carl V, Chun, Tae-Wook, Liao, Mei-June
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 18.04.2019
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The in vivo activity of a monoclonal antibody that targets the CD4 binding site on T cells and blocks HIV-1 binding was assessed. In this study of antiretroviral treatment interruption involving persons with HIV-1 infection, activity of UB-421 was shown.
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa1802264